Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces. InMed Pharmaceuticals […]

Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members

Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), is thrilled to welcome four seasoned professionals to its executive team. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, said the company was delighted to have […]

Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature

Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative disorders like ALS (amyotrophic lateral sclerosis) and multiple sclerosis (“MS”). In a recent Emerging Growth Conference 73 – Biotech Feature, Clene presented new findings and information pertinent to current and potential investors. Under the leadership of CEO Rob Etherington, […]

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the dosing completion of its human pilot study #2, GLP-1-H24-2. Lexaria’s patented DehydraTECH(TM) “drug delivery platform technology” increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain […]

D-Wave Quantum Inc. (NYSE: QBTS) Adds Second Annealing Quantum Computer in the U.S. and Unveils New Hybrid Quantum Solver

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, continues to make strides in the development and deployment of quantum computing technology. The company recently announced two major advancements: the introduction of a new hybrid quantum solver and the deployment of a second U.S.-based Advantage quantum computer. D-Wave has revealed plans […]

Annovis Bio Inc. (NYSE: ANVS) Announces New Data From Phase III Study of Buntanetap for Early Parkinson’s Disease

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease and Parkinson’s Disease, has released new data from its Phase III study of buntanetap for early Parkinson’s Disease. The study shows buntanetap is effective in enhancing both motor and cognitive functions, as well as non-motor […]

Nickel Rush Heats Up in Canada: Opening Doors for Companies Like Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) as Canada Eyes a Top Spot Among Global Producers

The global nickel market is experiencing a red-hot surge, driven by the electric vehicle revolution and questions about a potential supply shortage. Stainless steel remains the top use for nickel, but usage for batteries is forecast to jump for 7% of total use in 2021 to 41% by 2040. This trend is prompting major mining […]

 

From Our Blog

BlueSky AI Inc. (BSAI) Expands Market Presence with Strategic Milestones in AI Infrastructure

July 3, 2025

BlueSky AI (OTC: BSAI) has rapidly emerged as a key player in modular AI data center infrastructure, achieving major milestones in the past two years. The company has moved from concept to execution with its scalable SkyMod solutions, stepped up its market visibility by upgrading to the OTCID tier, and partnered with industry accelerators, marking significant […]

Rotate your device 90° to view site.